Osteoporosis therapy-dawn of the post-bisphosphonate era

Nature Reviews Endocrinology

Volumn 8, Issue 2, 2012, Pages 76-78

  Baron, Roland ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; DENOSUMAB; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PLACEBO; ROMOSOZUMAB; SCLEROSTIN; WNT PROTEIN; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE GROWTH; BONE MASS; BONE REMODELING; BONE STRENGTH; CARCINOGENICITY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIAGNOSTIC PROCEDURES; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMUR FRACTURE; FEMUR NECK; FOLLOW UP; FRAGILITY FRACTURE; GENE MUTATION; HIP; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; LUMBAR SPINE; MONOTHERAPY; MORBIDITY; MORTALITY; OSSIFICATION; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; VERTEBRA FRACTURE; DRUG RECALL; ENDOCRINOLOGY; METHODOLOGY; ORGANIZATION AND MANAGEMENT; TIME;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ENDOCRINOLOGY; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; SAFETY-BASED DRUG WITHDRAWALS; TIME FACTORS;

EID: 84856486407     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.207     Document Type: Review

References (10)

1. Cosman, F. et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503-511 (2011).
2. Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Gen. 10, 537-543 (2001). (Pubitemid 32184286)
3. Balemans, W. et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91-97 (2002). (Pubitemid 34146376)
4. Padhi, D. et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26 (2011).
5. Eastell, R. et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 530-537 (2011).
6. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
7. Boonen, S. et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. 96, 1727-1736 (2011).
8. Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972-980 (2011).
9. Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242-251 (2011).
10. Eastell, R. et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res. 26, 1303-1312